Physician profile
William Lee
NPI 1568550721
$929.86
in general payments reported to CMS, 2019-2025
20 companies · $185 in 2025
The $185 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.70 · 2020: $115 · 2021: $74.06 · 2022: $129 · 2023: $174 · 2024: $181 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $540.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $203.81 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Amgen INC. | $114.66 | 2021-2024 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $106.22 | 2024-2025 | Rexulti |
| Avanir Pharmaceuticals, INC. | $69.04 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $54.49 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $50.98 | 2020-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $45.85 | 2020 | |
| Biogen, INC. | $35.60 | 2020-2021 | |
| Novo Nordisk INC | $35.50 | 2025 | Ozempic |
| Opko Pharmaceuticals, LLC | $31.31 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.70 | 2025 | Caplyta |
| Neurocrine Biosciences, INC. | $28.57 | 2024 | Ingrezza |
| Dexcom, INC. | $19.66 | 2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $18.10 | 2022 | |
| Sumitomo Pharma America, INC. | $17.72 | 2023 | Gemtesa |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $16.25 | 2025 | Cologuard Collection Kit |
| Acadia Pharmaceuticals INC | $14.23 | 2023 | Nuplazid |
| Vifor Pharma, INC. | $13.28 | 2022 | |
| Mylan Specialty L.P. | $12.10 | 2020 | |
| Astellas Pharma US INC | $11.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.